ADG126 Mono + ADG126-anti PD1 + ADG126-ADG106
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Solid Tumors
Conditions
Advanced/Metastatic Solid Tumors
Trial Timeline
Mar 15, 2021 → May 17, 2024
NCT ID
NCT04645069About ADG126 Mono + ADG126-anti PD1 + ADG126-ADG106
ADG126 Mono + ADG126-anti PD1 + ADG126-ADG106 is a phase 1/2 stage product being developed by Adagene for Advanced/Metastatic Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT04645069. Target conditions include Advanced/Metastatic Solid Tumors.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Solid Tumors were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04645069 | Phase 1/2 | Completed |
Competing Products
20 competing products in Advanced/Metastatic Solid Tumors